News Releases

<< Back
Waters Licenses Mass Spectrometry Patent Portfolio from Bruker Daltonics

BOSTON, Aug 1, 2002 (BUSINESS WIRE) -- Bruker Daltonics Inc. (NASDAQ:BDAL) and Waters Corporation (NYSE:WAT) today announced the establishment of a framework for negotiation of future patent licensing agreements in the field of time-of-flight mass spectrometry (TOF-MS).

Within this framework, Waters has licensed a portfolio of mass spectrometry patents covering technology called Space-Velocity Correlation Focusing (SVCF), or Delayed Extraction (DE). This technology improves both accuracy and sensitivity in MALDI-TOF systems. As exclusive licensing agent, Bruker Daltonics has granted Waters a sub-license for a portfolio of SVCF patents owned by Indiana University, Applied Biosystems and Bruker Daltonics, in exchange for a one-time technology access fee and multi-year royalty payments. Financial terms of the sub-license were not disclosed.

Frank Laukien, President and CEO of Bruker Daltonics, and John Nelson, President of Waters said, "We are pleased to share intellectual property and feel that this cooperation will accelerate life science research and greatly benefit our customers."


Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit


Waters Corporation holds worldwide leading positions in three complementary analytical technologies - high performance liquid chromatography (HPLC), mass spectrometry (MS) and thermal analysis (TA). These markets account for $4.2 billion of the overall $19 billion analytical instrument market.


Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein.


Certain statements contained herein are forward looking. Many factors could cause actual results to differ from these statements, including loss of market share through competition, introduction of competing products by other companies, pressures on prices from competitors and/or customers, regulatory obstacles to new product introductions, lack of acceptance of new products, changes in the healthcare market and the pharmaceutical industry, changes in distribution of the Company's products, and foreign exchange fluctuations. Such factors are discussed in detail in the Company's filings with the Securities and Exchange Commission.

CONTACT: Bruker Daltonics Inc. Michael Willett, 978/663-3660, Ext. 1411 or Waters Corporation Gene Cassis, 508/482-2349